Evidence map›Paper›PMID 32990219›Full record

ArticleeLife2020

Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir.

Jason Neidleman, Xiaoyu Luo, Julie Frouard, Guorui Xie, Feng Hsiao, Tongcui Ma, Vincent Morcilla, Ashley Lee, Sushama Telwatte, Reuben Thomas and 14 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 93 citations in OpenAlex.

  1. The immunophenotype and proviral landscape of HIV-infected CD4 T cells during antiretroviral therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 6 institutions in 2 countries.

Jason Neidleman *Gladstone Institutes, San Francisco, United States.
Xiaoyu Luo *Gladstone Institutes, San Francisco, United States.
Julie FrouardGladstone Institutes, San Francisco, United States.
Guorui XieGladstone Institutes, San Francisco, United States.
Feng HsiaoGladstone Institutes, San Francisco, United States.
Tongcui MaGladstone Institutes, San Francisco, United States.
Vincent MorcillaCentre for Virus Research, the Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.ORCID 0000-0002-8159-6090
Ashley LeeCentre for Virus Research, the Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Sushama TelwatteSan Francisco Veterans Affairs (VA) Medical Center and University of California, San Francisco, San Francisco, United States.
Reuben ThomasGladstone Institutes, San Francisco, United States.
Whitney TamakiDepartment of Medicine, University of California, San Francisco, San Francisco, United States.
Benjamin WheelerDepartment of Medicine, University of California, San Francisco, San Francisco, United States.ORCID 0000-0001-5310-7213
Rebecca HohDivision of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, San Francisco, United States.
Ma SomsoukDepartment of Medicine, Division of Gastroenterology, San Francisco General Hospital and University of California, San Francisco, San Francisco, United States.
Poonam VohraDepartment of Pathology, University of California, San Francisco, San Francisco, United States.
Jeffrey MilushDepartment of Medicine, University of California, San Francisco, San Francisco, United States.
Katherine Sholtis JamesDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States.
Nancie M ArchinDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States.
Peter W HuntDivision of Experimental Medicine, University of California, San Francisco, San Francisco, United States.
Steven G DeeksDivision of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, San Francisco, United States.ORCID 0000-0001-6371-747X
Steven A YuklSan Francisco Veterans Affairs (VA) Medical Center and University of California, San Francisco, San Francisco, United States.
Sarah PalmerCentre for Virus Research, the Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Warner C GreeneGladstone Institutes, San Francisco, United States.
Nadia R RoanGladstone Institutes, San Francisco, United States.ORCID 0000-0002-5464-1976
Gladstone Institutes · USUniversity of California, San Francisco · USThe University of Sydney · AUSan Francisco VA Medical Center · USUniversity of North Carolina at Chapel Hill · USSan Francisco General Hospital · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
Delaney AIDS Research Enterprise to Cure HIVUM1AI126611 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT, PICKER, LOUIS J. · 2016 to 2020
$27.9M
Project 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruptionP01AI131374 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI ROAN, NADIA R · 2017 to 2021
$8.5M
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodesR01DK120387 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI LICHTERFELD, MATHIAS, YUKL, STEVEN A · 2019 to 2023
$4.1M
Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologiesR01AI147777 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2019 to 2022
$3.8M
Timing of ART and homeostasis of the persistent HIV reservoir in the adultR01AI116368 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUNT, PETER W · 2015 to 2019
$3.7M
Investigating Mechanisms of HIV Persistence in the GutR01DK108349 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI YUKL, STEVEN A · 2015 to 2019
$2.2M
The HIV Reservoir in Women: Implications for HIV cure interventionsR01AI134363 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARCHIN, NANCIE MARIE · 2017 to 2020
$2.2M
Elucidating the mechanism of progesterone-induced permissivity in the upperfemale reproductive tractR01AI127219 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2016 to 2020
$2.1M
Understanding HIV latency reversal and clearance of infected cells in vivoR01AI132128 · NIAID · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI WONG, JOSEPH K, YUKL, STEVEN A · 2017 to 2021
$1.9M
BD FACSAria II Flow CytometerS10RR028962 · NCRR · J. DAVID GLADSTONE INSTITUTES · PI CAVROIS, MARIELLE · 2011 to 2011
$544k
National Health and Medical Research Council APP1149990NCRR NIH HHS S10 RR028962NIAID NIH HHS P01 AI131374NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI116368NIAID NIH HHS R01 AI127219NIAID NIH HHS R01 AI132128NIAID NIH HHS R01 AI134363NIAID NIH HHS R01 AI147777NIAID NIH HHS UM1 AI126611NIDDK NIH HHS R01 DK108349NIDDK NIH HHS R01 DK120387Wellcome Trust 109301
6 · The paper itself

Abstract

The latent reservoir is a major barrier to HIV cure. As latently infected cells cannot be phenotyped directly, the features of the in vivo reservoir have remained elusive. Here, we describe a method that leverages high-dimensional phenotyping using CyTOF to trace latently infected cells reactivated ex vivo to their original pre-activation states. Our results suggest that, contrary to common assumptions, the reservoir is not randomly distributed among cell subsets, and is remarkably conserved between individuals. However, reservoir composition differs between tissues and blood, as do cells successfully reactivated by different latency reversing agents. By selecting 8-10 of our 39 original CyTOF markers, we were able to isolate highly purified populations of unstimulated in vivo latent cells. These purified populations were highly enriched for replication-competent and intact provirus, transcribed HIV, and displayed clonal expansion. The ability to isolate unstimulated latent cells from infected individuals enables previously impossible studies on HIV persistence.

Indexed as

CD4-Positive T-LymphocytesHIV-1HIV InfectionsCell SeparationHumansImmunophenotypingMass SpectrometryProvirusesVirus Latencyclonal expansionCyTOFHIVhumaninfectious diseasemicrobiologyreplication-competent reservoirtissuesvirus

Identifiers

PMID32990219
PMCPMC7524554
OpenAlexW3090882417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.